Zevra Therapeutics reported second quarter 2026 financial results with net revenue of $39.7 million, a 53% increase from the prior year period. MIPLYFFA contributed $30.2 million to this total, while the company held $260.2 million in cash and investments as of June 30, 2026. Net income was $8.8 million, or $0.14 per diluted share, compared to $74.7 million in Q2 2025 which included a one-time gain on the sale of a priority review voucher. The company also announced progress on its pipeline, including enrollment updates for the Phase 3 DiSCOVER trial of celiprolol and a request for re-examination of its Marketing Authorisation Application for arimoclomol in Europe. Zevra Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases.